Minimally invasive technologies are finding their way into the suites of ophthalmology surgeons. Just over the past six months, Allergan PLC has acquired two pre-commercial medtech companies developing miniature implants to treat glaucoma and dry eye disease. Meanwhile, Glaukos Corp., a leader in the micro-invasive glaucoma surgery (MIGS) market, remains one of the more successful medtech IPOs of late, raising more than $100 million in June and sporting a market capitalization of close to $1 billion built upon a successful commercial launch. [See Deal]
Medtech in ophthalmology is maturing. Surgical systems in the past centered around correcting vision with the implantation of artificial lenses,...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?